{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:19:48Z","timestamp":1789057188197,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T00:00:00Z","timestamp":1520553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1128644"],"award-info":[{"award-number":["OPP1128644"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.vaccine.2018.03.010","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T19:15:27Z","timestamp":1521227727000},"page":"2093-2103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Enhancing viral vaccine production using engineered knockout vero cell lines \u2013 A second look"],"prefix":"10.1016","volume":"36","author":[{"given":"F.","family":"Hoeksema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Karpilow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Luitjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lagerwerf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Havenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Groothuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gillissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.C.","family":"Lemckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Tripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Yallop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.03.010_b0005","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1128\/JVI.01464-15","article-title":"Engineering enhanced vaccine cell lines to eradicate vaccine-preventable diseases: the polio end game","volume":"90","author":"Van der Sanden","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.03.010_b0010","doi-asserted-by":"crossref","first-page":"170021","DOI":"10.1038\/sdata.2017.21","article-title":"Development of improved vaccine cell lines against rotavirus","volume":"4","author":"Wu","year":"2017","journal-title":"Sci Data"},{"key":"10.1016\/j.vaccine.2018.03.010_b0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines","volume":"8","author":"Barrett","year":"2009","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.03.010_b0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.csbj.2016.06.007","article-title":"A single-use strategy to enable manufacturing of affordable biologics","volume":"14","author":"Jacquemart","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.vaccine.2018.03.010_b0025","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00253-015-7267-9","article-title":"Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production","volume":"100","author":"Tapia","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2018.03.010_b0030","doi-asserted-by":"crossref","unstructured":"Rajendran R, Lingala R, Vuppu SK, Bandi BO, Manickam E, Macherla SR et al. Assessment of packed bed bioreactor systems in the production of viral vaccines. AMB Express 2014; 4\u201325.","DOI":"10.1186\/s13568-014-0025-z"},{"key":"10.1016\/j.vaccine.2018.03.010_b0035","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.vaccine.2012.10.070","article-title":"PER.C6\u00ae cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine","volume":"31","author":"Sanders","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.010_b0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/bit.24621","article-title":"Functional heterogeneity and heritability in CHO cell populations","volume":"110","author":"Davies","year":"2013","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2018.03.010_b0045","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.nbt.2014.02.002","article-title":"High-throughput ClonePix FL analysis of mAb-expressing clones using the UCOE expression system","volume":"31","author":"Hou","year":"2014","journal-title":"New Biotechnol"},{"key":"10.1016\/j.vaccine.2018.03.010_b0050","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/rcm.5011","article-title":"Rapid characterization of protein productivity and production stability of CHO cells by matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry","volume":"25","author":"Feng","year":"2011","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.vaccine.2018.03.010_b0055","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.03.010_b0060","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1016\/j.vaccine.2011.12.096","article-title":"Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011\u20132030","volume":"30","author":"Atherly","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.03.010_b0065","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/cid\/civ1013","article-title":"World health organization \u2013 coordinated global rotavirus surveillance network. global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000\u20132013","volume":"62","author":"Tate","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.03.010_b0070","doi-asserted-by":"crossref","unstructured":"Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis 2009;Suppl 1: S16\u2013S27.","DOI":"10.1086\/605026"},{"key":"10.1016\/j.vaccine.2018.03.010_b0075","doi-asserted-by":"crossref","first-page":"A140","DOI":"10.1016\/j.vaccine.2014.05.073","volume":"325","author":"Rheingans","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.010_b0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1542\/peds.2013-3849","article-title":"Rotavirus vaccines and health care utilization for diarrhea in the United States (2007\u20132011)","volume":"134","author":"Leshem","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.03.010_b0085","doi-asserted-by":"crossref","first-page":"e0166038","DOI":"10.1371\/journal.pone.0166038","article-title":"Skin vaccination against rotavirus using microneedles: proof of concept in gnotobiotic piglets","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.03.010_b0090","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/dnares\/dsu029","article-title":"The genome landscape of the African green monkey kidney-derived vero cell line","volume":"21","author":"Osada","year":"2014","journal-title":"DNA Res"},{"key":"10.1016\/j.vaccine.2018.03.010_b0095","doi-asserted-by":"crossref","unstructured":"Bakker WA, Thomassen YE, Van \u2018t Oever AG, Westdijk J, Van Oijen MG, Sundermann LC, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011;29:7188\u201396.","DOI":"10.1016\/j.vaccine.2011.05.079"},{"key":"10.1016\/j.vaccine.2018.03.010_b0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1369-703X(03)00180-3","article-title":"TubeSpin satellites: a fast track approach for process development with animal cells using shaking technology","volume":"17","author":"De Jesus","year":"2004","journal-title":"Biochem Eng J"},{"key":"10.1016\/j.vaccine.2018.03.010_b0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10616-011-9388-z","article-title":"Effects of clonal variation on growth, metabolism and productivity in response to trophic factor stimulation: a study of Chinese hamster ovary cells producing a recombinant antibody","volume":"64","author":"Dahodwala","year":"2012","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2018.03.010_b0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1586\/14760584.6.1.11","article-title":"Rotarix (RIX4414): an oral human rotavirus vaccine","volume":"6","author":"O\u2019Ryan","year":"2007","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.03.010_b0115","doi-asserted-by":"crossref","unstructured":"Knezevic I, Stacey G, Petricciani J, Sheets R. WHO Study Group on Cell Substrates. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22\u201323 April 2009, Bethesda, USA. Biologicals; 2010;38:162\u20139.","DOI":"10.1016\/j.biologicals.2009.08.019"},{"key":"10.1016\/j.vaccine.2018.03.010_b0120","first-page":"125","article-title":"The characterization of three monkey kidney cell lines","volume":"60","author":"Whitaker","year":"1985","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2018.03.010_b0125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","article-title":"Determination of 50% endpoint titer using a simple formula","volume":"5","author":"Ramakrishnan","year":"2016","journal-title":"World J Virol"},{"key":"10.1016\/j.vaccine.2018.03.010_b0130","unstructured":"https:\/\/www.unicef.org\/supply\/files\/OPV.pdf."},{"key":"10.1016\/j.vaccine.2018.03.010_b0135","unstructured":"https:\/\/www.unicef.org\/supply\/files\/IPV.pdf."},{"key":"10.1016\/j.vaccine.2018.03.010_b0140","unstructured":"http:\/\/cdn.doctorswithoutborders.org\/sites\/usa\/files\/attachments\/the_right_shot_2nd_edition.pdf."},{"key":"10.1016\/j.vaccine.2018.03.010_b0145","unstructured":"https:\/\/www.unicef.org\/supply\/files\/Rotavaccine.pdf."},{"key":"10.1016\/j.vaccine.2018.03.010_b0150","unstructured":"http:\/\/www.cidrap.umn.edu\/news-perspective\/2014\/03\/phase-3-results-boost-rotavirus-vaccine-developed-india."},{"key":"10.1016\/j.vaccine.2018.03.010_b0155","unstructured":"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d125."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18303463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18303463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:25:11Z","timestamp":1759400711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18303463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":31,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0264410X18303463"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.010","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing viral vaccine production using engineered knockout vero cell lines \u2013 A second look","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}